腾盛博药-B（股票代码：2137.HK）于6月17日宣布，公司董事会已批准一项股份回购计划，涉及资金总额不超过6,000万港元。
根据该计划，公司获授权回购的股份数量最多可达其已发行股份总数的10%。此举旨在优化公司资本结构，提升股东价值。
此次股份回购计划的具体实施将根据市场状况及公司资金安排，在符合相关法律法规的前提下进行。
腾盛博药-B（股票代码：2137.HK）于6月17日宣布，公司董事会已批准一项股份回购计划，涉及资金总额不超过6,000万港元。
根据该计划，公司获授权回购的股份数量最多可达其已发行股份总数的10%。此举旨在优化公司资本结构，提升股东价值。
此次股份回购计划的具体实施将根据市场状况及公司资金安排，在符合相关法律法规的前提下进行。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.